Lcar-Aio T Cells
Multiple Sclerosis
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
181 Active assets in the Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fampridine MGH Institute of Health Professions | Phase 4 | BBB |
Cladribine University Hospital, Strasbourg, France | Phase 4 | BBB |
Nabiximols Jazz Pharmaceuticals | Phase 4 | BBB |
Teriflunomide Sanofi | Phase 4 | BBB |
Ocrelizumab Polpharma Biologics International AG | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Lcar-Aio T Cells is also rated in:
myelin oligodendrocyte glycoprotein antibody-associated diseaseActive
CC
Indicative · Phase 1
43 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →